Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

Proteasome inhibition is a validated strategy for therapy of multiple myeloma, but this disease remains challenging as relapses are common, and often associated with increasing chemoresistance. Moreover, nonspecific proteasome inhibitors such as bortezomib can induce peripheral neuropathy and other...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Kuhn, Deborah J., Hunsucker, Sally A., Chen, Qing, Voorhees, Peter M., Orlowski, Marian, Orlowski, Robert Z.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2009
Pynciau:
Lymphoid Neoplasia
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2680370/
https://ncbi.nlm.nih.gov/pubmed/19050304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-07-171637
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg